Technical success · people with infrapopliteal arterial lesions in chronic limb‐threatening ischaemia
PTA probably leads to higher technical success ITT No. of limbs: 476 (5 RCTs) compared with stent (moderate certainty).
2 findings from 1 review
OR 3 [1.14, 7.93]
Studies not reported
Moderate
OR 2.78 [1.04, 7.41]
Studies not reported
Moderate
Procedural complications · people with infrapopliteal arterial lesions in chronic limb‐threatening ischaemia
PTA showed no clear difference in procedural complications ITT No. of participants: 360 (5 RCTs) compared with stent (moderate certainty).
2 findings from 1 review
OR 0.87 [0.01, 53.6]
Studies not reported
Moderate
OR 0.84 [0.01, 47.7]
Studies not reported
Moderate
Primary patency ( · people with infrapopliteal arterial lesions in chronic limb‐threatening ischaemia
PTA showed no clear difference in primary patency < 6 months ITT No. of lesions: 456 (3 RCTs) compared with stent (moderate certainty).
2 findings from 1 review
OR 0.88 [0.37, 2.11]
Studies not reported
Moderate
OR 0.97 [0.32, 3]
Studies not reported
Moderate
Mortality TA No. of participants: 487 (6 RCTs) · people with infrapopliteal arterial lesions in chronic limb‐threatening ischaemia
PTA showed no clear difference in mortality TA No. of participants: 487 (6 RCTs) compared with stent (moderate certainty).
1 finding from 1 review
OR 0.7 [0.42, 1.15]
Studies not reported
Moderate
Acceptability ‐ total dropouts · patients with cancer and depression
It is very uncertain whether selective serotonin reuptake inhibitors (SSRIs) changes dropouts due to any cause (acceptability) compared with tricyclic antidepressants (TCAs) (very low certainty).
1 finding from 1 review
Immunisation schedule up to date Interviews with mothers, record reviews · patients with improving immunisation uptake among children < 2 years whose vaccination is not up to date
LHWs to promote immunisation uptake in children probably leads to higher immunisation schedule up to date Interviews with mothers, record… compared with usual care (moderate certainty).
1 finding from 1 review
Improvement in vertigo · adults with acute attacks of vestibular migraine
It is very uncertain whether triptans changes improvement in vertigo (global score) ‐ up to 2 hours compared with placebo (very low certainty).
1 finding from 1 review
Change in vertigo · adults with acute attacks of vestibular migraine
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Serious adverse events · adults with acute attacks of vestibular migraine
1 finding from 1 review
Uptake of testing · patients with uptake of HIV testing
On site voluntary testing and counselling probably leads to higher uptake of testing compared with voucher (moderate certainty).
1 finding from 1 review
Mental state: significant response or improvement in negative symptoms (PANSS negative subscale, high = worse) ‐ short term (12 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes mental state: significant response or improvement in negative… compared with placebo (very low certainty).
1 finding from 1 review
Mental state: 2. Positive symptoms ‐ average endpoint score PANSS positive subscore · adults with schizophrenia
1 finding from 1 review
Clinical global response: significant response or improvement in global status (CGI‐S, high = worse) ‐ short term (4 weeks) · adults with schizophrenia
It is very uncertain whether noradrenaline reuptake inhibitors changes clinical global response: significant response or improvement in… compared with placebo (very low certainty).
1 finding from 1 review
Cognitive functioning: significant response or improvement in cognitive functioning · adults with schizophrenia
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Cognitive function: average endpoint score** · adults with schizophrenia
1 finding from 1 review
QoL · adults with schizophrenia
1 finding from 1 review
Nausea · adults with schizophrenia
Noradrenaline reuptake inhibitors showed no clear difference in adverse effects: Nausea ‐ short term (2 to 12 weeks) compared with placebo (low certainty).
1 finding from 1 review
Participant‐reported pain relief of 50% or greater · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher self‐reported pain relief of 50% or greater compared with placebo (low certainty).
1 finding from 1 review
Patient Global Impression of Change much or very much improved · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors may leads to higher patient Global Impression to be much or very much improved (PGIC) compared with placebo (low certainty).
1 finding from 1 review
Fatigue · patients with fibromyalgia
Serotonin noradrenaline reuptake inhibitors showed no clear difference in self‐reported fatigue (20‐100 scale) Higher scores indicate higher… compared with placebo (low certainty).
1 finding from 1 review